Dimensional Fund Advisors LP Has $46.11 Million Stake in NeoGenomics, Inc. (NASDAQ:NEO)

Dimensional Fund Advisors LP lifted its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 7.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,324,624 shares of the medical research company’s stock after acquiring an additional 217,687 shares during the period. Dimensional Fund Advisors LP owned approximately 2.60% of NeoGenomics worth $46,108,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in NEO. Blue Trust Inc. lifted its holdings in shares of NeoGenomics by 107.2% in the second quarter. Blue Trust Inc. now owns 2,331 shares of the medical research company’s stock worth $32,000 after acquiring an additional 1,206 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in NeoGenomics by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,434 shares of the medical research company’s stock valued at $136,000 after buying an additional 1,791 shares in the last quarter. Banque Cantonale Vaudoise grew its stake in shares of NeoGenomics by 10.2% during the second quarter. Banque Cantonale Vaudoise now owns 17,575 shares of the medical research company’s stock worth $244,000 after buying an additional 1,633 shares during the last quarter. Gabelli Funds LLC acquired a new position in shares of NeoGenomics during the first quarter worth $283,000. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in shares of NeoGenomics in the 1st quarter valued at $314,000. 98.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

NEO has been the topic of a number of research reports. Benchmark restated a “buy” rating and set a $18.00 price objective on shares of NeoGenomics in a research report on Tuesday, September 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of NeoGenomics in a research note on Wednesday, September 25th. Finally, Stephens reiterated an “overweight” rating and set a $19.00 target price on shares of NeoGenomics in a research report on Tuesday, July 30th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, NeoGenomics has an average rating of “Moderate Buy” and a consensus price target of $19.89.

NeoGenomics Stock Down 1.0 %

Shares of NASDAQ NEO opened at $14.50 on Monday. The company’s 50 day moving average price is $16.06 and its 200-day moving average price is $14.92. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.93 and a current ratio of 2.01. NeoGenomics, Inc. has a 52-week low of $11.03 and a 52-week high of $21.22. The company has a market capitalization of $1.85 billion, a P/E ratio of -21.97 and a beta of 1.19.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Monday, July 29th. The medical research company reported $0.03 EPS for the quarter. NeoGenomics had a negative net margin of 12.50% and a negative return on equity of 2.72%. The business had revenue of $164.50 million for the quarter, compared to analysts’ expectations of $161.82 million. During the same quarter in the prior year, the firm posted ($0.09) earnings per share. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. Equities analysts forecast that NeoGenomics, Inc. will post -0.22 earnings per share for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.